I’m simply not seeing the negativity here that others are. Mortality IS the endpoint. This is not an apples to oranges comparison (vs placebo) anymore, it’s vs SOC - 24% reduction vs SOC is gigantic. I realize some were hoping for 30% or higher, but there is absolutely no possible way IMO that we cannot be granted an EUA with at the very least a phase 4 continuation. If not, the FDA can say buh-bye to 1.3m+ vials of this drug as it will be on its way to Brazil for their winter. I bought more stock today and could give a damn what it does Monday because BILLIONS of dollars of revenue are forthcoming, and, eventually a major stockpiling of the drug likely here and elsewhere for BILLIONS more. The table is set.